Aditx Therapeutics (ADTX)
(Delayed Data from NSDQ)
$0.50 USD
+0.02 (4.20%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $0.48 -0.02 (-3.23%) 6:06 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Aditxt Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 1 | 0 | 0 | 0 |
Cost Of Goods | 1 | 1 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 26 | 26 | 42 | 9 | 6 |
Income After Depreciation & Amortization | -26 | -25 | -42 | -9 | -6 |
Non-Operating Income | -2 | -1 | -4 | 0 | 0 |
Interest Expense | 4 | 1 | 0 | 0 | 0 |
Pretax Income | -32 | -28 | -46 | -9 | -6 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -32 | -28 | -46 | -9 | -6 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -32 | -28 | -46 | -9 | -6 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -23 | -23 | -40 | -9 | -6 |
Depreciation & Amortization (Cash Flow) | 3 | 2 | 2 | 0 | 0 |
Income After Depreciation & Amortization | -26 | -25 | -42 | -9 | -6 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.30 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -108.15 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -108.15 | -595.60 | -4,860.00 | -2,660.00 | NA |
Fiscal Year end for Aditxt Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.04 | 0.08 | 0.08 | 0.12 | 0.22 |
Cost Of Goods | 0.02 | 0.07 | 0.29 | 0.11 | 0.19 |
Gross Profit | 0.02 | 0.01 | -0.20 | 0.02 | 0.04 |
SG&A, R&D, and Dept/Amort Expenses | 5.99 | 11.55 | 7.74 | 8.11 | 4.26 |
Income After SG&A, R&D, and Dept/Amort Expenses | -5.97 | -11.54 | -7.94 | -8.09 | -4.22 |
Non-Operating Income | -0.56 | -0.84 | -1.22 | -0.74 | -0.16 |
Interest Expense | 1.09 | 2.49 | 1.81 | 0.91 | 1.29 |
Pretax Income | -7.62 | -14.87 | -10.98 | -9.75 | -5.68 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | -0.07 | -0.14 | -0.01 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -7.62 | -14.87 | -10.98 | -9.75 | -5.68 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -7.55 | -14.73 | -10.97 | -9.75 | -5.68 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1.80 | 1.61 | NA | 0.20 | 0.15 |
Diluted EPS Before Non-Recurring Items | -4.19 | -9.14 | NA | -48.77 | -36.80 |
Diluted Net EPS (GAAP) | -4.19 | -9.14 | 29.82 | -48.77 | -36.80 |